{"filings":[{"id":121492,"accession_number":"0001193125-25-332152","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.03","8.01","9.01"],"status":"ready","headline":"Clearside Biomedical bankruptcy court approves sale process; Health Ocean Limited as stalking horse","event_type":"other_material","confidence":"high","bullets":["Court approved bidding procedures on Dec 19, 2025; Health Ocean Limited designated as stalking horse bidder.","Monthly operating report: $3.05M cash; net loss of $490,885 for seven days ending Nov 30, 2025.","Total assets negative $24.4M, equity negative $26.9M; prepetition unsecured debt $2.3M.","No employee payroll; no professional fees paid during period; court authorized tax payments.","Sale process subject to higher or better offers; auction to follow bidding procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121491,"accession_number":"0001193125-25-311305","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clearside Biomedical files Form 25 to complete Nasdaq delisting after Chapter 11 bankruptcy","event_type":"other_material","confidence":"high","bullets":["Filed Form 25 on Dec 8, 2025 to delist from Nasdaq and deregister under Section 12(b); effective no earlier than Dec 18, 2025.","Nasdaq delisting notice received Nov 24, 2025 after Chapter 11 filing (Case No. 25-12109); trading suspended Dec 1, 2025.","Common stock trades on OTC Pink under symbol CLSDQ since Dec 1, 2025.","Deregistration will reduce SEC reporting obligations 90 days after Form 25 effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121490,"accession_number":"0001193125-25-297177","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.03","3.01","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical files for Chapter 11 bankruptcy; Nasdaq delisting effective Dec 1","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition on Nov 23, 2025 in Delaware (Case No. 25-12109).","Nasdaq delisting notice received; trading suspended Dec 1, moving to OTC under symbol CLSDQ.","Company intends to sell substantially all assets through a Section 363 auction.","First-day motions filed to continue normal operations during the bankruptcy process.","Assets include SCS Microinjector platform, CLS-AX program, and multiple licensing deals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121489,"accession_number":"0001193125-25-233470","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Clearside Biomedical regains Nasdaq minimum bid price compliance via reverse split","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq Panel letter on Oct 6, 2025 confirming compliance with Minimum Bid Price Requirement.","Compliance achieved by maintaining closing bid at $1.00+ for 10 consecutive business days after reverse stock split.","Reverse stock split effective Sept 12, 2025 was approved by stockholders and implemented to cure non-compliance.","Non-compliance notice originally received Feb 7, 2025; delisting hearing held Sept 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138168,"accession_number":"0001193125-25-200747","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Clearside Biomedical files 1-for-15 reverse stock split, reduces authorized shares to 26.7M","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective September 12, 2025 at 5:00 p.m. ET; split-adjusted trading begins September 15, 2025.","Every 15 outstanding shares combine into 1; no fractional shares issued – cash in lieu.","Authorized common stock reduced from 400M to 26,666,666; par value unchanged at $0.001.","Proportionate adjustments to stock options, RSUs, warrants, and equity plan reserves.","New CUSIP 185063203; Nasdaq ticker CLSD unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138167,"accession_number":"0000950170-25-114089","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.","Authorized shares reduced from 400M to 26,666,666; no change to par value.","Trading on split-adjusted basis on Nasdaq Capital Market starting Sept 15, 2025; new CUSIP 185063203.","No fractional shares; cash paid in lieu; proportionate adjustments to stock options, RSUs, warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138166,"accession_number":"0000950170-25-113362","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap","event_type":"other_material","confidence":"high","bullets":["Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.","Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.","Purchaser waived right to foreclose on Seller capital stock in specified circumstances.","All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138165,"accession_number":"0001193125-25-194994","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.","Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.","At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.","Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138164,"accession_number":"0000950170-25-108846","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.","Clearside intends to request a hearing before Nasdaq Panel to stay delisting; stock will continue trading pending hearing process.","Company is seeking stockholder approval for a reverse stock split at ratio 1-for-5 to 1-for-15 to regain minimum bid price compliance.","Anthony Gibney resigned as Chairperson and board member effective Aug 11, 2025; appointed CFO of Aura Biosciences; no dispute.","Board appointed existing member Clay B. Thorp as new Chairperson effective Aug 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138163,"accession_number":"0000950170-25-096438","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Clearside explores strategic alternatives; all employees terminated, R&D paused","event_type":"other_material","confidence":"high","bullets":["All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.","Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.","Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.","No agreement reached; no timetable set; no assurance any transaction will occur.","CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155598,"accession_number":"0000950170-25-079689","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.","All three director nominees (Lasezkay, Shaffer, Gibney) were elected with >25M votes for.","Advisory vote on executive compensation approved: 18.9M for, 3.4M against, 6.8M abstain.","Ratification of Ernst & Young as auditor for FY2025 approved: 48.5M for, 1.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155597,"accession_number":"0000950170-25-071386","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.","Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.","Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.","Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.","Cash $13.6M at March 31, expected to fund operations into Q4 2025."],"consensus_eps_estimate":-1.6611,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2330000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174091,"accession_number":"0000950170-25-046085","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).","Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.","FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.","Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.","Tony Gibney appointed Chair of Board effective November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174090,"accession_number":"0000950170-25-019866","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clearside Biomedical receives Nasdaq minimum bid price deficiency notice","event_type":"regulatory","confidence":"high","bullets":["Notice received Feb 7, 2025; stock below $1.00 for 30 consecutive business days.","Company has 180 days (until Aug 6, 2025) to regain compliance.","To cure, bid price must close at $1.00+ for 10 consecutive business days.","Options include transfer to Nasdaq Capital Market or reverse stock split.","Failure to comply may result in delisting; company intends to monitor and seek remedies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}